Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)

被引：0

作者：

Yap, Y. S. ^{[1
]}

Masuda, N. ^{[2
]}

Ito, Y. ^{[3
]}

Ishikawa, T. ^{[4
]}

Kim, S. J. ^{[5
]}

Aruga, T. ^{[6
]}

Toyama, T. ^{[7
]}

Saeki, T. ^{[8
]}

Yamanaka, T. ^{[9
]}

Saito, M. ^{[10
]}

Watanabe, J. ^{[11
]}

Takahashi, M. ^{[12
]}

Nakamura, S. ^{[13
]}

Inoue, K. ^{[14
]}

Suarez-Vizcarra, J. ^{[15
]}

He, W. ^{[15
]}

Solovieff, N. ^{[16
]}

Su, F. ^{[15
]}

Chiu, J. ^{[17
]}

机构：

[1] Natl Canc Ctr, Med Oncol, Singapore, Singapore

[2] Osaka Natl Hosp, Med Oncol, Osaka, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Med Oncol, Tokyo, Japan

[4] Tokyo Med Univ Hosp, Med Oncol, Tokyo, Japan

[5] Osaka Univ Hosp, Med Oncol, Osaka, Japan

[6] Tokyo Komagome Hosp, Med Oncol, Tokyo, Japan

[7] Nagoya City Univ, Grad Sch Med Sci, Med Oncol, Nagoya, Aichi, Japan

[8] Saitama Med Univ, Med Oncol, Int Med Ctr, Saitama, Japan

[9] Kanagawa Canc Ctr, Med Oncol, Yokohama, Kanagawa, Japan

[10] Juntendo Univ Hosp, Med Oncol, Tokyo, Japan

[11] Shizuoka Canc Ctr, Med Oncol, Nagaizumi, Shizuoka, Japan

[12] Hokkaido Canc Ctr, Natl Hosp Org, Med Oncol, Sapporo, Hokkaido, Japan

[13] Showa Univ Hosp, Breast Ctr, Tokyo, Japan

[14] Saitama Canc Ctr, Med Oncol, Saitama, Japan

[15] Novartis Pharmaceut, Novartis Oncol, E Hanover, NJ USA

[16] Novartis Inst BioMed Res, Biomarkers & Diagnost Biometr, Cambridge, MA USA

[17] Queen Mary Hosp, Med Oncol, Hong Kong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

10.1093/annonc/mdy428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

400

引用

页码：13 / +

页数：2

共 50 条

[41] Ribociclib in HR-positive, HER2-negative breast cancer [J].

Burki, Talha Khan .

LANCET ONCOLOGY, 2016, 17 (11) :E482-E482

[42] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity [J].

Frassoldati, Antonio ;

Biganzoli, Laura ;

Bordonaro, Roberto ;

Cinieri, Saverio ;

Conte, Pierfranco ;

De Laurentis, Michelino ;

Del Mastro, Lucia ;

Gori, Stefania ;

Lauria, Rossella ;

Marchetti, Paolo ;

Michelotti, Andrea ;

Montemurro, Filippo ;

Naso, Giuseppe ;

Pronzato, Paolo ;

Puglisi, Fabio ;

Tondini, Carlo Alberto .

FUTURE ONCOLOGY, 2020, 16 (05) :129-145

[43] Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) plus endocrine therapy (ET) in Asian patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [J].

Yap, Y. S. ;

Su, F. ;

Joshi, M. ;

Chiu, J. ;

Masuda, N. ;

Ito, Y. ;

Ishikawa, T. ;

Aruga, T. ;

Kim, S. J. ;

Deore, U. ;

Babbar, N. ;

Balbin, A. .

ANNALS OF ONCOLOGY, 2021, 32 :S459-S460

[44] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer [J].

Kahraman, Seda ;

Erul, Enes ;

Seyyar, Mustafa ;

Gumusay, Ozge ;

Bayram, Ertugrul ;

Demirel, Burcin Cakan ;

Acar, Omer ;

Aksoy, Sercan ;

Baytemur, Naziyet Kose ;

Sahin, Elif ;

Cabuk, Devrim ;

Basaran, Gul ;

Paydas, Semra ;

Yaren, Arzu ;

Guven, Deniz Can ;

Erdogan, Atike Pinar ;

Demirci, Umut ;

Yasar, Alper ;

Bayoglu, Ibrahim Vedat ;

Hizal, Mutlu ;

Gulbagci, Burcu ;

Paksoy, Nail ;

Davarci, Sena Ece ;

Yilmaz, Funda ;

Dogan, Ozlem ;

Orhan, Sibel Oyucu ;

Kayikcioglu, Erkan ;

Aytac, Ali ;

Keskinkilic, Merve ;

Mocan, Eda Eylemer ;

Unal, Olcun Umit ;

Aydin, Esra ;

Yucel, Hakan ;

Isik, Deniz ;

Eren, Onder ;

Uluc, Basak Oyan ;

Ozcelik, Melike ;

Hacibekiroglu, Ilhan ;

Aydiner, Adnan ;

Demir, Hacer ;

Oksuzoglu, Berna ;

Cilbir, Ebru ;

Cubukcu, Erdem ;

Cetin, Bulent ;

Oktay, Esin ;

Erol, Cihan ;

Okutur, Sadi Kerem ;

Yildirim, Nilgun ;

Alkan, Ali ;

Selcukbiricik, Fatih .

FUTURE ONCOLOGY, 2023, :727-736

[45] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer [J].

Lim, Bora ;

Potter, David A. ;

Salkeni, Mohamad A. ;

Silverman, Paula ;

Haddad, Tufia C. ;

Forget, Frederic ;

Awada, Ahmad ;

Canon, Jean-Luc ;

Danso, Michael ;

Lortholary, Alain ;

Bourgeois, Hugues ;

Tan-Chiu, Elizabeth ;

Vincent, Sylvie ;

Bahamon, Brittany ;

Galinsky, Kevin J. ;

Patel, Chirag ;

Neuwirth, Rachel ;

Leonard, E. Jane ;

Diamond, Jennifer R. .

CLINICAL CANCER RESEARCH, 2021, 27 (12) :3329-3338

[46] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer [J].

Garrigos, Laia ;

Camacho, Daniela ;

Perez-Garcia, Jose Manuel ;

Llombart-Cussac, Antonio ;

Cortes, Javier ;

Antonarelli, Gabriele .

EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) :949-958

[47] DOSE-DEPENDENT RELATION BETWEEN METFORMIN AND THE RISK OF HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE (HR+/HER2-) BREAST CANCER AMONG POSTMENOPAUSAL WOMEN WITH TYPE-2 DIABETES [J].

Chikermane, S. ;

Trivedi, M., V ;

Sharma, M. ;

Abughosh, S. M. ;

Aparasu, R. R. ;

Johnson, M. L. .

VALUE IN HEALTH, 2021, 24 :S43-S43

[48] Immunotherapy for hormone receptor-positive HER2-negative breast cancer [J].

Cardoso, Fatima ;

Hirshfield, Kim M. ;

Kraynyak, Kimberly A. ;

Tryfonidis, Konstantinos ;

Bardia, Aditya .

NPJ BREAST CANCER, 2024, 10 (01)

[49] PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE [J].

Andre, F. ;

Marinsek, N. ;

Ricci, J. F. ;

Etchberger, J. ;

Degun, R. ;

Benelli, G. ;

Saletan, S. ;

Jerusalem, G. .

VALUE IN HEALTH, 2012, 15 (07) :A419-A419

[50] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy [J].

Engel-Nitz, Nicole M. ;

Hao, Yanni ;

Rogerio, Jaqueline Willemann ;

Turnbull, James D. ;

Rey, Gabriel Gomez ;

Sullivan, Jane ;

Rossof, Arthur H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)

← 1 2 3 4 5 →